Acute Lymphoblastic Leukaemia research hub
5 indexed studies · 1 currently recruiting
- recruitingPHASE1, PHASE2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
This study is looking into a new drug, AZD3632, for certain blood cancers like leukaemia and myelodysplastic syndromes. It aims to check its safety, how well it works, and how the body handles it, both on its own and with another medicine.
United States · Australia · Canada - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
This study looks at new ways to treat acute myeloid leukaemia (AML) after a stem cell transplant. It combines two medicines, venetoclax and azacitidine, to see if they are safe and help people live longer and healthier lives after their transplant.
Czechia · Hungary · Spain - active not recruitingPHASE3
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
This study looks at new ways to treat children with a type of blood cancer called Acute Myeloid Leukaemia (AML). It compares different chemotherapy drugs, including a drug called gemtuzumab ozogamicin, and different types of stem cell transplants to find the most effective and safest treatments for young patients.
Australia · France · Ireland - active not recruitingPHASE2, PHASE3
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
This study looks at new treatments for adults with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) who are having a stem cell transplant. It aims to improve transplant success and reduce relapse.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia
This study is looking at a new way to treat a type of blood cancer called acute myeloid leukaemia (AML) with a specific gene change (FLT3-ITD). We want to see if the medicine, Xospata, can completely clear tiny traces of cancer cells in the body.
Greece